Meeting
2014 ASCO Annual Meeting
ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
Authors
Tae Gyun Kwon
Kyungpook National University Medical Center, Daegu, South Korea
Tae Gyun Kwon , Seo Seong II, Seok-Soo Byun , Hideaki Miyake , Takeshi Ueda , Dingwei Ye , Jesús García-Donas , Marine Gross-Goupil , Thomas E. Hutson , Robert DeBenedetto , Subramanian Hariharan , Min Young Lee , Rolf Gerhard Linke , Fumito Tsuji , David I. Quinn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01599754
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4595^)
DOI
10.1200/jco.2014.32.15_suppl.tps4595
Abstract #
TPS4595^
Poster Bd #
160A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
First Author: Paul E. Goss
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang
Poster
2022 ASCO Annual Meeting
Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.
First Author: Toni K. Choueiri
Poster
2022 ASCO Annual Meeting
C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin